Exsurco Medical

Exsurco Medical, founded in 2016, has developed the proprietary Amalgatome platform, a rotary dermatome technology designed for superior maneuverability and consistent tissue thickness. The company commercializes two product lines: the Amalgatome MD and SK for tissue bank (cadaveric) use, and the Amalgatome SD, an FDA-cleared surgical device for skin grafting and debridement in burn and trauma surgery. Early clinical testimonials and a peer-reviewed consensus paper highlight significant potential benefits in operative speed, graft quality, and donor site yield, positioning Exsurco as a disruptive player in the established dermatome market.

Proprietary rotary dermatome platform for precise, maneuverable skin graft harvesting and wound debridement, enabling consistent tissue thickness and dual-function (debride/harvest) capability.

Exsurco competes in the dermatome market against large, established medical device companies like Zimmer Biomet (with its dermatome products). Its competitive edge is based on its innovative rotary technology, which claims superior maneuverability and efficiency, and the unique dual debridement/harvesting function of its surgical device, which addresses unmet needs in surgical workflow.